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Summary Aplidine is a new marine anti-cancer depsipeptide isolated from the Mediterranean tunicate Aplidium albicans. We have evaluated
its antiproliferative action against a variety of freshly explanted human tumour specimens. Concentration ranges of 0.01-1.0 gM and
0.0001-1.0 liM were used in short- and long-term exposure schedules respectively. After exposure for 1 h in 49 evaluable specimens, aplidine
showed a clear concentration-dependent anti-tumour effect. At 0.05 ,UM, 85% of the specimens were markedly inhibited. Continuous exposure
for 21-28 days in 54 tumour specimens also led to a concentration-dependent activity relationship. Fifty per cent and 100% tumour inhibitions
were achieved with 0.001 ,UM and 0.05 gM respectively. A head to head evaluation assessing short vs continuous exposure was carried out,
resulting in evidence of an activity-time of exposure relationship. Breast, melanoma and non-small-cell lung cancer appear to be sensitive to
low concentrations of aplidine. In addition the evaluation of the effects of aplidine on haematopoietic cells showed a concentration-dependent
toxicity. However, under continuous exposure, active concentrations induced mild bone marrow toxicity, indicating that a therapeutic window
at marginally myelotoxic concentrations might exist.
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Aplidine is a new marine-derived anti-cancer chemical entity
identified from the Mediterranean tunicate Aplidium albicans.
Aplidine is a cyclic depsipeptide (Figure 1) structurally related to
other naturally occurring didemnins. In contrast to the present
candidate, those compounds are only found in various species
of a Caribbean tunicate genus, Trididemnin (Sakai et al, 1996).
Aplidine shows potent in vitro activity against human tumour solid
cell lines, especially non-small-cell lung and colon tumour cells
with IC50 values at 0.18 nM and 0.45 nm respectively (Faircloth et
al, 1995; Lobo et al, 1997). The National Cancer Institute's (NCI)
human in vitro panel has confirmed selectivity for non-small-cell
lung cancer (NSCLC), melanoma, ovarian and colorectal cancer
cell lines (Faircloth et al, 1996).
Initial studies with this marine depsipeptide suggested in vivo
activity against murine tumours such as B116 melanoma (Faircloth
et al, 1995). Moreover, additional in vivo studies performed in
mice bearing human xenografted tumours confirm activity against
breast MX-1 and colon CX-1 (Faircloth et al, 1996).
The didemnins exert their anti-tumour effect by interfering with
protein synthesis via GTP-dependent inhibition of the elongation
factor 1-alpha, a protein translation component (Crews et al,
1994). Aplidine induces, in vitro and in vivo, a total inhibition of
omithine decarboxylase activity at very low concentrations
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(10-10M) (Urdiales et al, 1996). However, the importance of this
finding has to be investigated further to understand whether this
biochemical effect might be ofrelevance as a therapeutic interven-
tion (Auvinen, 1997). A recent in vitro study indicates that the
cytotoxicity of aplidine might also be related to the intracellular
overaccumulation of spermidine and spermine (Gomez-Fabre et
al, 1997). An ongoing study is currently addressing the elucidation
of additional cellular protein receptors as targets for the
didemnins. Preliminary data have identified palmitoyl thioesterase
as a binding protein for aplidine and the biological consequences
of the interaction with this lysosomal enzyme are under investiga-
tion (Crews et al, 1996).
The present study evaluates the in vitro antiproliferative effect
of aplidine in human tumours explanted from patients and human
bone marrow.
MATERIAL AND METHODS
Compounds
Aplidine was provided by Pharma Mar, Tres Cantos, Madrid,
Spain, as a white powder with a chromatographic purity of 98.50%
(HPLC assay). The source of the compound was semisynthetic,
being synthetized in three steps from natural didemnin A (Rinehart
et al, 1991). 'H nuclear magnetic resonance (NMR) and fast atom
bombardment mass spectroscopy (FABMS) spectra ofthe synthetic
compound were identical in all aspects with natural aplidine. Stock
solutions and final solutions of aplidine were prepared in dimethyl
sulphoxide (DMSO, Serva, Heidelberg, Germany). Doxorubicin
was purchased from Farmitalia Carlo Erba, Freiburg, Germany.
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Figure 1 Chemical structure of Aplidine
Tumour cells were incubated with aplidine for 1 h before
transfer ofthe tumour cell-agar-medium mixture into 100-gl glass
capillaries. Final concentrations of aplidine were 0.01, 0.05, 0.1,
0.5 and 1.0 tmol 1-'.
For long-term exposure (21-28 days), final concentrations of
aplidine were 0.0001, 0.001, 0.01, 0.05, 0.1, 0.5 and 1.0 grmol 1-'.
Human tumour cloning system
Tumour specimens were obtained by sterile procedures as part of
routine clinical measures. Biopsies of solid tumours were stored
in McCoy's SA medium containing 5% fetal calf serum (FCS),
10 mmol 1' hydroxyethylpiperazine ethanesulphonic acid
(Hepes), 1 mmol 1-' sodium pyruvate, 90 U ml-' penicillin and
90 gg ml-' streptomycin (all Gibco, Paisley, UK) for transport to
the laboratory. Preservative-free heparin (10 U ml-', Novo
Nordisk, Mainz, Germany) was added immediately after collec-
tion offluids to prevent coagulation. Solid specimens were minced
and repeatedly passed through metal meshes with mesh widths of
100 gm and 50 ,um (Linker, Kassel, Germany) to obtain a single-
cell suspension. Effusions were centrifuged at 112 g for 5-7 min
and passed through 25-g needles to obtain single cell suspensions
when necessary. Cells were cryopreserved in culture medium
containing 10% DMSO by freezing at a rate of-2°C min-' down to
-175°C and stored in liquid nitrogen. Before experiments, the cells
were thawed and the DMSO removed.
The capillary soft-agar cloning system was used as described
previously (Maurer and Ali-Osman, 1981; Hanauske et al, 1985;
Von Hoff et al, 1986). Briefly, cells from tumour specimens were
seeded at a median density of 2.3 x 104 cells per capillary (range
1.5 x 104-6.3 x 104 cells per capillary) in 100-jl glass capillaries
(Brand, Wertheim, Germany) in a mixture of 0.3% agar (Sigma,
Deisenhofen, Germany) in double-enriched Connaught Medical
Research Laboratories' (CMRL) Medium 1066 (Gibco)
containing 15% horse serum (Gibco), 2% fetal calf serum,
0.3 mmol 1-' vitamin C (Sigma), 90 U ml-' penicillin, 90 jg ml-'
streptomycin, 10mmol 1-1 Hepes, 2 mmol 1-1 sodium pyruvate,
0.1 mmol 1-' non-essential amino acids (Gibco), 4 mmol 1-' gluta-
mine (Gibco), 100 jg ml-' asparagine (Gibco), 4 ng ml-' hydro-
cortisone (Sigma), 50 U ml-' catalase (Serva) and 0.1 nmol 1-'
epidermal growth factor (Flow, Meckenheim, Germany).
For each data point, six capillary tubes were used. Each experi-
ment contained one set of controls with 0.1% DMSO as solvent
and a second set with 1 mmol 1-' ammonium monovanadate
Microscopic
determination of colony formation
Figure 2 Methodology of the soft agar cloning of freshly explanted human
tumours
(Merck, Darmstadt, Germany), to ensure the presence of a good
single-cell suspension (Hanauske et al, 1987). The colony forma-
tion was evaluated with an inverted microscope after an incubation
period of 21-28 days at 37°C, 5% carbon dioxide and 100%
humidity. Colony formation was considered adequate when the
DMSO control had a mean of at least 18 colonies per six capil-
laries and the vanadate control showed < 30% colony formation
compared with DMSO. Tumour specimens were considered to be
sensitive ifclonogenic growth was < 0.5 x control.
Effects on clonogenic haematopoietic stem cells
Cells from frozen peripheral stem cell harvests were thawed and
seeded at a density of 105 cells per plate in Petri dishes (Nunc,
Naperville, IL, USA) in MethoCult H4431 medium (StemCell
Technologies, Vancouver, Canada) containing 10% fetal calf
serum and 1% glutamine. Colony-forming units were evaluated
with an inverted microscope after an incubation period of 10-14
days at 37°C, 5% carbon dioxide and 100% humidity and were
classified as CFU-GEMM, CFU-GM, BFU-E and cluster (Bradley
et al, 1968). Final concentrations of aplidine were 0.0001-
0.1 .tmol 1-'. Doxorubicin was tested at concentrations of 1.0-, 0.1-
and 0.01-fold the relevant clinical peak plasma concentrations
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Table 1 Inhibitory activity of aplidine against tumour colony-forming units
from freshly explanted human tumours in vitro using a short-term exposure
schedule (1 h)
Tumour type Aplidine (gmol l-1)
0.01 0.05 0.1 0.5 1.0
Breast 3/11a 9/11 10/11 11/11 11/11
Melanoma 1/11 6/11 9/11 11/11 11/11
Ovarian 5/11 10/11 11/11 11/11 11/11
Stomach 1/3 2/3 3/3 3/3 3/3
NSCLC 1/4 4/4 4/4 4/4 4/4
NHL 3/3 3/3 3/3 3/3 3/3
Colon 2/3 3/3 3/3 3/3 3/3
Sarcoma 0/2 2/2 2/2 2/2 2/2
Hodgkin's lymphoma
Lymphoma 1/1 1/1 1/1 1/1 1/1
Total 17/49 40/49 46/49 49/49 49/49
(35%) (82%) (94%) (100%) (100%)
aNumber of inhibited specimens (<50% survival of tumour colony-forming
units) over number of evaluable specimens.
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Figure 4 Aplidine. Colony growth inhibition. Long-term exposure (21-28
days); median colony growth inhibition at different concentrations
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Figure 3 Aplidine. Colony growth inhibition. Short-term exposure (1 h);
median colony growth inhibition at different concentrations
observed (i.e. 0.7, 0.07 and 0.007 tmol 1-'). Clonogenic growth of
haematopoietic stem cells was considered to be sensitive if it was
< 0.5 x control.
Statistical analysis
Data were calculated as means and standard deviations of at least
three evaluable determinations per data point. Colony survival was
calculated by expressing the average number of colony-forming
units from cells exposed to each anti-tumour agent relative to the
average number of colony-forming units from untreated controls.
Results were evaluated statistically by the Friedman repeated
measures ANOVA on ranks test. P-values < 0.05 were interpreted
as indicating significant differences.
The experimental design is summarized in Figure 2.
RESULTS
A total of56 tumours were included in this experiment. Forty-nine
specimens (88%) showed adequate growth in controls using
short-term exposure schedules and 54 specimens (96%) showed
adequate growth in controls using long-term exposure schedules.
The tumour types tested were mainly breast carcinoma, melanoma,
ovarian carcinoma, lung carcinoma, colorectal carcinoma, gastric
carcinoma and lymphoma.
As shown in Table 1 and Figure 3 for the short-term exposure,
aplidine has a profound inhibitory effect on tumour colony forma-
tion. The anti-tumour effect is concentration dependent. At
0.01 ,umol 1-1, in vitro growth of 17/49 (35%) evaluable specimens
was inhibited; at 0.05,mol 1-', 40/49 (82%) specimens were
inhibited; and at concentrations > 0.5 ,tmol 1-', colony formation
of49/49 (100%) tumours was inhibited.
The comparison of median reductions of colony formation also
demonstrates that aplidine is active at > 0.01 ,umol 1-1. Moreover,
ovarian, lymphoma and colorectal cancer specimens appear to be
selectively sensitive to the lowest concentration, 0.01 g.mol 1-l?
tested in a short-term exposure schedule.
For continuous exposure experiments, concentrations ranged
from 0.0001 tmol 1-' to 1.0 tmol 1-'. Again, the data show a
concentration-dependent anti-tumour activity (Figure 4, Table 2).
The lowest active concentration evaluated, 0.001 tmol 1-',
suggests that non-small-cell lung cancer, melanoma, and breast
cancer might be highly sensitive to this compound at long-term
exposure.
The indication that a better activity profile is achievable by
using a continuous exposure schedule led to prospective head to
head comparisons of short-term vs long-term drug exposures. As
shown in Figure 5A-C, the inhibition oftumour-forming units was
more pronounced with the long-term exposure. This argues for a
schedule-dependent activity ofaplidine in vitro.
The toxicity on haematopoietic stem cells is summarized in
Tables 3 and 4. The IC5 of aplidine appears to be in the range of
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Table 2 Inhibitory activity of aplidine against tumour colony-forming units from freshly explanted human tumours in vitro using a long-term exposure schedule
(21-28 days)
Tumour type Aplidine (umol 1-')
0.0001 0.001 0.01 0.05 0.1 0.5 1.0
Breast 0/7a 3/7 12/13 12/12 12/12 12/12 12/12
Melanoma 0/10 6/10 11/12 12/12 12/12 12/12 12/12
Ovarian 0/3 0/3 11/11 11/11 11/11 11/11 11/11
Stomach 0/1 1/1 3/3 3/3 3/3 3/3 3/3
NSCLC 1/4 3/4 4/4 3/3 3/3 3/3 3/3
NHL 1/3 1/3 4/4 3/3 3/3 3/3 3/3
Colorectal 0/1 0/1 3/3 3/3 3/3 3/3 3/3
Sarcoma n.d. n.d. 2/2 2/2 2/2 2/2 2/2
Hodgkin's lymphoma 0/1 1/1 1/1 1/1 1/1 1/1 1/1
SCLC n.d. n.d. 1/1 1/1 1/1 1/1 1/1
Total 2/30 15/30 52/54 51/51 51/51 51/51 51/51
(7%) (50%) (94%) (100%) (100%) (100%) (100%)
aNumber of inhibited specimens (< 50% survival of tumour colony forming units) over number of evaluable specimens. n.d., not done.
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Figure 5 In vitro colony growth inhibition with aplidine comparing short-
vs. long-term exposure. (A) breast cancer. (B) melanoma. (C) non-small-cell
lung cancer
British Journal ofCancer (1998) 78(6), 739-744
A
100
0
c
0
0)
c
0
0
0
80
60
40
20
0
C
100
0
0
20
0
80
60
40
20
0
0.0001 0.001 0.01 0.05 0.1 0.5 1.0
Aplidine (lmol l-1)
0 CancerResearch Campaign 1998In vitro anti-tumouractivity ofaplidine 743
Table 3 Toxicity of aplidine in comparison with doxorubicin on clonogenic haematopoietic stem cells in vitro using a short-term exposure schedule (1 h)
Type Aplidine (grmol 1-') Doxorubicin (jimol 1-')
0.01 0.05 0.1 0.007 0.07 0.7
%S ± s.d.a %S ± s.d. %S ± s.d. %S ± s.d. %S ± s.d. %S ± s.d.
CFU-GEMM 97+25 40+8 49+16 65+15 76+16 0
CFU-GM 126+27 43+10 47+7 65±8 73+5 23+2
BFU-E 90+24 52±9 48±6 99+13 99+13 8+2
Cluster 101+25 55+11 67+11 73+11 69±21 32+4
Inhibitory anti-tumour activity 35% 82% 94%
aSurvival (% control) ± standard deviation.
Table 4 Toxicity of aplidine in comparison with doxorubicin on clonogenic haematopoietic stem cells in vitro using a long-term exposure schedule
Type Aplidine (jmol 1-') Doxorubicin (gmol 1-')
0.0001 0.001 0.01 0.007 0.07 0.7
%S ± s.d.a %S ± s.d. %S ± s.d. %S ± s.d. %S ± s.d. %S ± s.d.
CFU-GEMM 114±25 76+13 73±16 96+19 14+3 0
CFU-GM 99+8 98±8 40+3 107+9 4±1 0
BFU-E 98±9 89+8 45±4 91 +11 3+1 0
Cluster 98+5 100+11 95+5 94+5 4±1 0
Inhibitory anti-tumour activity 7% 50% 94%
0.05 imol 1-} for short-term exposure (CFU-GEMM, CFU-GM,
BFU-E and cluster). At this concentration, 82% of tumour speci-
mens are inhibited (colony growth < 0.5 x control), with high in
vitro activity against breast, melanoma, ovarian, colon, lymphoma
and non-small-cell lung cancer. In addition, tumour inhibition at
subtoxic concentrations, 0.01 ltM, is observed in ovarian and colon
cancer and lymphoma. Concentrations in the range of 0.02-
0.03 ,umol 1-' showed similar toxicity to doxorubicin at clinically
relevant concentrations. For the long-term exposure, the IC50 of
aplidine is 0.01 gmol 1- (CFU-GM and BFU-E). At this concen-
tration, between 50% and 94% of the tumours are inhibited
(colony growth < 0.5 x control). Moreover, marginally myelotoxic
concentrations of aplidine, 0.001 gM, yielded to tumour inhibition
in breast, melanoma and non-small-cell lung cancer.
DISCUSSION
Aplidine is a new marine-derived anti-cancer candidate struc-
turally related to didemnin B, the first marine anti-cancer
compound to enter clinical trials (Chun et al, 1986). In fact,
didemnin B was the subject of a large phase I/II programme spon-
sored by the US National Cancer Institute (Bethesda, MD, USA).
Initial phase I trials were performed in the early 1980s, but dose
escalation was hampered by the onset of severe emesis (Doff et al,
1988; Stewart et al, 1991). As a result, subsequent phase II studies
included suboptimal dose levels, but minor responses were
observed in non-small-cell lung cancer and prostatic cancer. Later,
a new dose escalation programme with aggressive antiemetic
protection was implemented and determined a new maximum
tolerable dose and also ofnew dose-limiting toxicities, specifically
cardiac and neuromuscular (Shin et al, 1991). A number of phase
II studies incorporating a higher optimal dose were conducted, and
positive results in heavily treated patients with low-grade non-
Hodgkin's lymphoma (NHL) have recently been presented (Kucuk
et al, 1996). The overall data from the phase II programme with
didemnin B indicate that repeated cycles of therapy are hampered
by acute cardiotoxicity and neurotoxicity. However, the innovative
features ofthe didemnin family as potential anti-cancer entities led
to the establishment of a discovery programme searching for
active derivatives with differential toxicities and better therapeutic
indexes (Faircloth et al, 1995).
Aplidine has been identified as a new generation didemnin that
harbours interesting differential patterns in terms of the mecha-
nism of action, potency and toxicological profile (Faircloth et al,
1996). An in vitro study assessing the cardiotoxic potential ofapli-
dine confirms a lack of cardiotoxic effect at active concentrations
(Faircloth et al, 1995). In this experiment, the parent compound,
didemnin B, shows clear evidence ofcardiotoxicity at anti-tumour
in vitro concentrations. Moreover, early data from an in vitro study
comparing the neurotoxic potential ofaplidine and didemnin B, in
a murine clonal phaeochromocytoma cell line PC12 (Geldof,
1995), indicate a better therapeutic index for aplidine and confirm
the possibility of inducing a marked anti-tumour effect at non-
neurotoxic concentrations.
The present report uses an in vitro cloning system with freshly
explanted human tumours and clearly shows a concentration-
dependent anti-tumour activity. Interestingly, the current work
indicates that a better anti-tumour effect is achieved when tumour
cells are continuously exposed to the study drug. Moreover, it
appears that tumour types such as colon cancer, non-small-cell
lung cancer, melanoma, breast and ovarian cancer and lymphomas
might be a target for further development. Recent in vivo data
confirm activity against human Burkitt's lymphoma and prostatic
PC3 androgen-independent tumour models. In addition, the
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pattern of tumour inhibition is consistent with a cytostatic effect,
supporting a time of exposure-activity relationship in the in vivo
setting (Faircloth et al, 1997).
In addition, evaluation of the myelotoxic potential of aplidine
has been the subject of the present investigation. Its in vitro
haematotoxicity is both affected by concentration and time of
exposure. This part of our study suggests the feasibility of
improving its therapeutic index by continuous exposure of
aplidine, with concentrations of 0.001 tM inducing anti-tumour
effects but mild toxicity in bone marrow progenitors. Ofnote is the
observation that myelotoxicity has been a rare event in phase II
studies with didemnin B, even at optimal dose levels (Malfetano et
al, 1993, 1996; Kucuk et al, 1996).
In summary, the current in vitro investigation identifies a
number of tumour types that are sensitive to low concentrations of
aplidine. The magnitude of its anti-tumour effect is dependent on
the time of exposure and seems to be achievable at non-myelo-
toxic concentrations. Aplidine is under late preclinical develop-
ment, and phase I trials incorporating prolonged/protracted
infusions are planned.
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